10th Edition of The International Pharmacopoeia
Recommendation

Thursday, 29 October 2026 9 .00 - 17.15 h
AI/ML-based Methods for Optimizing Pharmaceutical Research Processes
The International Pharmacopoeia (Ph. Int.) contains recommended procedures for analysis and specifications for pharmaceutical substances (active pharmaceutical ingredients, APIs) and dosage forms. According to the WHO (World Health Organization) it is intended to serve as source for reference or adaptation by any WHO Member State. The Ph. Int. has legal status, whenever a national or regional authority refers to it in appropriate legislation.
Compared to other pharmacopoeias (e.g. Ph. Eur., USP, JP), "priority is given to medicines included in the WHO Model List of Essential Medicines and to medicines which are important for WHO health programmes and for which other pharmacopoeias do not offer any test specifications". Moreover, the needs of developing countries are taken into account.
The International Pharmacopoeia, Tenth Edition, 2020 - Content Overview
- General Notices (includes information on storage, stability, labelling, identity, tests & assays, accuracy and precision, calculation of results, impurities, reference substances, etc.)
- Appendices to the General Notices
Abbreviations and symbols
Units of measurement
Names, symbols, and relative atomic masses of certain elements - Monographs
Pharmaceutical substances
Dosage forms
Radiopharmaceuticals - Methods of Analysis
1. Physical and Physicochemical Methods
2. Chemical methods
3. Biological methods
4. Methods for materials of plant origin
5. Pharmaceutical technical procedures - Infrared reference spectra
- Reagents, test solutions and volumetric solutions
- Supplementary information
The International Pharmacopoeia is available online free for use.
Related GMP News
26.08.2026GMP and "Planned Deviations" - a Contradiction?
19.08.2026Why Root Cause Analysis is the Key to efficient CAPA
19.08.2026EMA updates Guideline on implementing the Shortage Prevention Plan
19.08.2026FDA: Simplified Registration for U.S. Sites and Greater Complexity for Non-U.S. Sites
12.08.2026When Training Fails: FDA Warning Letters Highlight GMP Training Deficiencies in 2026
29.07.2026EU-GMP for Veterinary Medicinal Products: What will change in Switzerland?


